Keros Therapeutics Inc (KROS) Price to Earnings Ratio

Corporate emblem and logo of Keros Therapeutics Inc (KROS)

High costs for final hematological drug testing and liquidity risks are creating pressure, which is reflected in the market P/E ratio of Keros Therapeutics (KROS), where -3.20 expresses the metric's value today. Business stability relies on the precision delivery of biologics via a network of thermo-hubs. Simultaneously, Keros Therapeutics (KROS) is implementing protein pathway tuning methods for blood and muscle restoration.

Keros Corp (KROS) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Keros Therapeutics, Inc. (KROS)

General company analysis:Keros Therapeutics Inc - KROS
Original product of kerostx.com

Keros Therapeutics' innovative approach to protein modulation and its patent protection in the rare disease sector establish a foundation for high future margins. By analyzing the price-to-earnings ratio, an investor assesses the relationship between market capitalization and net income, which allows for determining the extent of overpayment for the asset or identifying the business's undervaluation relative to its current ability to generate profit.